Yumanity Proteostasis Regulators EP3552664A1, 15th Apr
Summary
The European Patent Office published patent application EP3552664A1 for proteostasis regulators filed by Yumanity, Inc., with inventors Megan Foley, Bradley Tait, and Matthew Cullen. The application, classified under IPC A61P 25/28 for neurological therapeutic use, was published on April 15, 2026 and designates all standard European member states. This publication establishes Yumanity's exclusive intellectual property rights over the claimed compounds and their therapeutic applications.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
The EPO published European patent application EP3552664A1, granting Yumanity, Inc. exclusive intellectual property rights over proteostasis regulators for therapeutic use. The patent, classified under A61P 25/28, names Megan Foley, Bradley Tait, and Matthew Cullen as inventors and designates all standard European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
For pharmaceutical and biotechnology companies developing treatments for protein misfolding diseases, this patent establishes Yumanity's proprietary position in the proteostasis modulator space. Competitors pursuing similar mechanisms of action should conduct freedom-to-operate analyses to assess potential licensing needs or design-around strategies for their compound development programs.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROTEOSTASIS REGULATORS
Publication EP3552664A1 Kind: A1 Apr 15, 2026
Applicants
Yumanity, Inc.
Inventors
FOLEY, Megan, TAIT, Bradley, CULLEN, Matthew
IPC Classifications
A61P 25/28 20060101AFI20190812BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.